Ironwood Looking for Associate Director of Market Research, Customer Insights

Ironwood Pharmaceuticals is hiring an associate director of market research and customer insights who will conduct market research and analysis for the company’s in-line product LINZESS, a treatment for irritable bowel syndrome with constipation in adults.

The associate director will report to the senior director of market research and competitive intelligence and will be tasked with planning, designing and executing both primary and secondary qualitative and quantitative market research to provide actionable insights and recommendations to inform decision-making.

The position will help develop the annual market research plan and budget, collaborate with co-promotion partners, identify and manage market research vendors, and use appropriate market research techniques to perform analysis of key customer segments to identify leverage points, an announcement on LinkedIn said.

The ideal candidate must have a bachelor’s degree with more than 10 years of experience in performing qualitative and quantitative market research within a pharmaceutical, health care or biotech company.

Key qualifications also include having the ability to identify and articulate insights and recommendations to influence outcomes at executive levels; having a comprehensive understanding of common primary and secondary market research methodologies, applications and techniques; experience in managing multiple vendors and agency partners; and a thorough understanding of the patient flow, buying process and influencers.

Ironwood Pharmaceuticals was founded in 1998 out of the Whitehead Institute for Biomedical Research, an affiliate of Massachusetts Institute of Technology.

In May, the commercial biotechnology company and AbbVie announced their plans to discontinue the development of MD-7246, a candidate therapy for treating adult patients with abdominal pain associated with irritable bowel syndrome with diarrhea, after the Phase II trial did not meet its primary or key secondary endpoints.